The present invention provides methods for identifying human cancer patients whose cancerous cells overexpress the 17-1A antigen to such an extent as determined herein that the patients may be considered as suitable for treatment with a therapeutic 17-1A antigen binding agent such as an antibody. Preferably the therapeutic antibody is Edrecolomab. Kits for use in such methods and methods of treating patients so identified are also provided.
